SCHEMBL4800593

SCHEMBL4800593

NC(=O)c1cnc([CH]Cc2ccccc2)nc1-c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 2/20 0.41
PDE4B Q07343 3/20 0.40
ALDH1A1 P00352 3/20 0.40
LMNA P02545 2/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
ATM Q13315 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
PARP1 P09874 1/20 0.39
JAK2 O60674 1/20 0.38
JAK1 P23458 1/20 0.38
TYK2 P29597 1/20 0.38
JAK3 P52333 1/20 0.38
IRAK4 Q9NWZ3 1/20 0.38
STAT6 P42226 3/20 0.37
BCAT2 O15382 1/20 0.36
RXFP1 Q9HBX9 2/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4560200 0.74 CDC7 (0.56) LMNAMEN1KMT2APARP1JAK2
SCHEMBL4153937 0.69 GAA (0.40) ALDH1A1LMNAMAPK1SMN1; SMN2MEN1
SCHEMBL4210739 0.69 TAAR1 (0.39) ALDH1A1MEN1KMT2APARP1KDM4E
SCHEMBL5172649 0.68 PARP1 (0.46) MEN1KMT2APARP1JAK2BCAT2
SCHEMBL4560249 0.67 KCNH2 (0.46) ALDH1A1MEN1KMT2APARP1BCAT2
SCHEMBL4138010 0.67 PARP1 (0.43) MAPK1PARP1JAK2JAK1TYK2
SCHEMBL30315919 0.66 BCAT2 (0.46) ALDH1A1MEN1KMT2APARP1BCAT2
SCHEMBL13723824 0.65 PARP1 (0.49) PDE4BALDH1A1LMNAMAPTMAPK1
SCHEMBL4150980 0.65 MEN1 (0.49) ALDH1A1LMNAMAPTMAPK1SMN1; SMN2
SCHEMBL6616377 0.64 BCAT2 (0.47) ALDH1A1MAPTMEN1KMT2APARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7429604-B2 Six-membered heterocycles useful as serine protease inhibitors BRISTOL MYERS SQUIBB COMPANY (US) 2008-09-30 US disclosed
US-20060009455-A1 especially blood coagulation factor XIa and plasma kallikrein; e.g. 4-aminomethyl-[2-phenyl-1-(4-phenyl-pyridin-2-yl)-ethyl]-trans cyclohexanecarboxamide; anticoagulant, antiinflammatory agent; BRISTOL-MYERS SQUIBB COMPANY 2006-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009455-A1 especially blood coagulation factor XIa and plasma kallikrein; e.g. 4-aminomethyl-[2-phenyl-1-(4-phenyl-pyridin-2-yl)-ethyl]-trans cyclohexanecarboxamide; anticoagulant, antiinflammatory agent; F12, F11, F2 THRB 3567/4885PDE4B 2367/4885ALDH1A1 4211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.